207 related articles for article (PubMed ID: 38424044)
21. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
22. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract][Full Text] [Related]
23. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
Adamia S; Bhatt S; Wen K; Chyra Z; Fell GG; Tai YT; Pioso MS; Abiatari I; Letai A; Dorfman DM; Hideshima T; Anderson KC
Leukemia; 2022 Apr; 36(4):1088-1101. PubMed ID: 35082402
[TBL] [Abstract][Full Text] [Related]
25. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
26. Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Clark AS; Makhlin I; DeMichele A
Clin Cancer Res; 2021 Jan; 27(2):371-373. PubMed ID: 33144339
[TBL] [Abstract][Full Text] [Related]
27. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
Al-Rashdan A; Quirk S; Roumeliotis M; Abedin T; Amaro CP; Barbera L; Lupichuk S; Cao JQ
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):399-408. PubMed ID: 35870712
[TBL] [Abstract][Full Text] [Related]
28. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
[TBL] [Abstract][Full Text] [Related]
29. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
Tian Q; Gao H; Zhou Y; Yang J
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Bertolini I; Crucitta S; Fontanelli L; Rofi E; De Angelis C; Diodati L; Cavallero D; Gianfilippo G; Salvadori B; Fogli S; Falcone A; Scatena C; Naccarato AG; Roncella M; Ghilli M; Morganti R; Fontana A; Danesi R
Breast Cancer Res Treat; 2019 Nov; 178(1):57-62. PubMed ID: 31346846
[TBL] [Abstract][Full Text] [Related]
31. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
[TBL] [Abstract][Full Text] [Related]
32. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
34. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M; Crucitta S; Lorenzini G; De Angelis C; Diodati L; Cavallero D; Bargagna I; Cinacchi P; Fratini B; Salvadori B; Ghilli M; Roncella M; Fontana A; Danesi R; Cucchiara F
Pharmacol Res; 2021 Jan; 163():105241. PubMed ID: 33049397
[TBL] [Abstract][Full Text] [Related]
35. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.
Uzhachenko RV; Bharti V; Ouyang Z; Blevins A; Mont S; Saleh N; Lawrence HA; Shen C; Chen SC; Ayers GD; DeNardo DG; Arteaga C; Richmond A; Vilgelm AE
Cell Rep; 2021 Apr; 35(1):108944. PubMed ID: 33826903
[TBL] [Abstract][Full Text] [Related]
36. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
[TBL] [Abstract][Full Text] [Related]
37. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
[TBL] [Abstract][Full Text] [Related]
39. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Haricharan S; Punturi N; Singh P; Holloway KR; Anurag M; Schmelz J; Schmidt C; Lei JT; Suman V; Hunt K; Olson JA; Hoog J; Li S; Huang S; Edwards DP; Kavuri SM; Bainbridge MN; Ma CX; Ellis MJ
Cancer Discov; 2017 Oct; 7(10):1168-1183. PubMed ID: 28801307
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.
Guo X; Chen H; Zhou Y; Shen L; Wu S; Chen Y
Expert Opin Investig Drugs; 2022 Sep; 31(9):933-944. PubMed ID: 35786092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]